Abstract
Objective
SUMO-specific protease 3 (SENP3), a member of the SUMO-specific protease family, reverses the SUMOylation of SUMO-2/3 conjugates. Dysregulation of SENP3 has been proven to be involved in the development of various tumors. However, its role in mantle cell lymphoma (MCL), a highly aggressive lymphoma, remains unclear. This study was aimed to elucidate the effect of SENP3 in MCL.
Methods
The expression of SENP3 in MCL cells and tissue samples was detected by RT-qPCR, Western blotting or immunohistochemistry. MCL cells with stable SENP3 knockdown were constructed using short hairpin RNAs. Cell proliferation was assessed by CCK-8 assay, and cell apoptosis was determined by flow cytometry. mRNA sequencing (mRNA-seq) was used to investigate the underlying mechanism of SENP3 knockdown on MCL development. A xenograft nude mouse model was established to evaluate the effect of SENP3 on MCL growth in vivo.
Results
SENP3 was upregulated in MCL patient samples and cells. Knockdown of SENP3 in MCL cells inhibited cell proliferation and promoted cell apoptosis. Meanwhile, the canonical Wnt signaling pathway and the expression of Wnt10a were suppressed after SENP3 knockdown. Furthermore, the growth of MCL cells in vivo was significantly inhibited after SENP3 knockdown in a xenograft nude mouse model.
Conclusion
SENP3 participants in the development of MCL and may serve as a therapeutic target for MCL.
Similar content being viewed by others
References
Wilson MR, Barrett A, Cheah CY, et al. How I manage mantle cell lymphoma: indolent versus aggressive disease. Br J Haematol, 2023,201(2):185–198
Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J, 2019,9(6):50
Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol, 2019,94(6):710–725
Zhang Y, Ma Y, Wu G, et al. SENP1 promotes MCL pathogenesis through regulating JAK-STAT5 pathway and SOCS2 expression. Cell Death Discov, 2021,7(1):192
Fernàndez V, Hartmann E, Ott G, et al. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol, 2005,23(26):6364–6369
Klener P. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level. Expert Opin Ther Targets, 2020,24(10):1029–1045
Zhang H, Chen Z, Miranda RN, et al. TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy. Cancer Res, 2016,76(21):6410–6423
Kunz K, Piller T, Müller S. SUMO-specific proteases and isopeptidases of the SENP family at a glance. J Cell Sci, 2018,131(6):jcs211904
Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol, 2010,11(12):861–871
Li J, Liang L, Jiang L, et al. Viral RNA-binding ability conferred by SUMOylation at PB1 K612 of influenza A virus is essential for viral pathogenesis and transmission. PLoS Pathog, 2021,17(2):e1009336
Stokes S, Almire F, Tatham MH, et al. The SUMOylation pathway suppresses arbovirus replication in Aedes aegypti cells. PLoS Pathog, 2020,16(12):e1009134
Chang H, Yeh E. SUMO: From Bench to Bedside. Physiol Rev, 2020,100(4):1599–1619
Han Y, Huang C, Sun X, et al. SENP3-mediated deconjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress. J Biol Chem, 2010,285(17):12906–12915
Huang C, Han Y, Wang Y, et al. SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. Embo J, 2009,28(18):2748–2762
Nishida T, Yamada Y. The nucleolar SUMO-specific protease SMT3IP1/SENP3 attenuates Mdm2-mediated p53 ubiquitination and degradation. Biochem Biophys Res Commun, 2011,406(2):285–291
Zhou Z, Wang M, Li J, et al. SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer. Oncogene, 2016,35(45):5826–5838
Ren YH, Liu KJ, Wang M, et al. De-SUMOylation of FOXC2 by SENP3 promotes the epithelial-mesenchymal transition in gastric cancer cells. Oncotarget, 2014,5(16):7093–7104
Yan S, Sun X, **ang B, et al. Redox regulation of the stability of the SUMO protease SENP3 via interactions with CHIP and Hsp90. Embo J, 2010,29(22):3773–3786
Louche A, Blanco A, Lacerda TLS, et al. Brucella effectors NyxA and NyxB target SENP3 to modulate the subcellular localisation of nucleolar proteins. Nat Commun, 2023,14(1):102
Wu X, Li JH, Xu L, et al. SUMO specific peptidase 3 halts pancreatic ductal adenocarcinoma metastasis via deSUMOylating DKC1. Cell Death Differ, 2023,30(7):1742–1756
Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood, 2011,117(1):26–38
Vega F, Davuluri Y, Cho-Vega JH, et al. Side population of a murine mantle cell lymphoma model contains tumour-initiating cells responsible for lymphoma maintenance and dissemination. J Cell Mol Med, 2010,14(6B):1532–1545
Chan WK, Williams J, Sorathia K, et al. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. Exp Hematol Oncol, 2023,12(1):79
Sloan SL, Brown F, Long M, et al. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma. Blood, 2023,142(10):887–902
Yeh ET, Gong L, Kamitani T. Ubiquitin-like proteins: new wines in new bottles. Gene, 2000,248(1–2):1–14
Hang J, Dasso M. Association of the human SUMO-1 protease SENP2 with the nuclear pore. J Biol Chem, 2002,277(22):19961–19966
Eifler K, Vertegaal ACO. SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. Trends Biochem Sci, 2015,40(12):779–793
Zhao Y, Yang B, Chen D, et al. Combined identification of ARID1A, CSMD1, and SENP3 as effective prognostic biomarkers for hepatocellular carcinoma. Aging (Albany NY), 2021,13(3):4696–4712
Tong Y, Zhang Z, Cheng Y, et al. Hypoxia-induced NFATc3 deSUMOylation enhances pancreatic carcinoma progression. Cell Death Dis, 2022,13(4):413
Long X, Zhao B, Lu W, et al. The Critical Roles of the SUMO-Specific Protease SENP3 in Human Diseases and Clinical Implications. Front Physiol, 2020,11:558220
Gelebart P, Anand M, Armanious H, et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood, 2008,112(13):5171–5179
Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer, 2008,8(5):387–398
Cao X, Wang X, Zhang W, et al. WNT10A induces apoptosis of senescent synovial resident stem cells through Wnt/calcium pathway-mediated HDAC5 phosphorylation in OAjoints. Bone, 2021,150:116006
Wang J, Yang Q, Tang M, et al. Validation and analysis of expression, prognosis and immune infiltration of WNT gene family in non-small cell lung cancer. Front Oncol, 2022,12:911316
Cesarato N, Schwieger-Briel A, Gossmann Y, et al. Short anagen hair syndrome: Association with mono- and biallelic variants in WNT10A and a genetic overlap with male pattern hair loss. Br J Dermatol, 2023,189(6):741–749
Sun X, Fang J, Ye F, et al. Diffuse Large B-Cell Lymphoma Promotes Endothelial-to-Mesenchymal Transition via WNT10A/Beta-Catenin/Snail Signaling. Front Oncol, 2022,12:871788
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors have declared no competing interests in this work.
Additional information
This study was supported by the Chongqing Natural Science Foundation (No. 2023NSCQ-MSX3161 and No. cstc2020jcyj-msxmX1058) and the National Natural Science Foundation of China (No. 81800172).
Supplementary data
Rights and permissions
About this article
Cite this article
Ma, Yn., Zou, Yd., Liu, Zl. et al. SENP3 Promotes Mantle Cell Lymphoma Development through Regulating Wnt10a Expression. CURR MED SCI 44, 134–143 (2024). https://doi.org/10.1007/s11596-024-2829-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-024-2829-7